OBJECTIVES: Department of Veterans Affairs (VA) patients in depression treatment have high suicide rates after psychiatric hospitalization, antidepressant starts, and dosage changes. Policy makers have recommended closer monitoring during these periods to reduce suicide. This study assessed the frequency of high-risk periods in clinical settings, the levels of monitoring provided during these periods, and the estimated costs of providing monitoring consistent with the most stringent Food and Drug Administration recommendation for treatment periods after antidepressant change (seven visits in the first 12 weeks). METHODS: Monitoring visits were identified in the 12-week period after antidepressant starts and dosage changes and after discharge from psychiatric hospitalization for 100,000 randomly selected VA patients in depression treatment between April 1, 1999, and September 30, 2004. Incremental costs of providing intensive monitoring were estimated by using VA Health Economics Resource Center average cost data. RESULTS: Patients averaged less than one high-risk period each year. They completed an average of 2.4 monitoring visits during the 12-week period after antidepressant treatment events and 4.9 visits after psychiatric hospitalization. Providing intensive monitoring would cost an additional $408-$537 for each high-risk period after antidepressant treatment events and $313-$341 for each high-risk period after psychiatric hospitalization. During fiscal year 2004 providing intensive monitoring during all high-risk periods would have cost an additional $183-$270 million. Providing intensive monitoring only after psychiatric hospitalizations would have cost an additional $15-$17 million. CONCLUSIONS: Providing intensive monitoring for VA patients in depression treatment during all high-risk periods for suicide would require substantial services reorganization and incremental expenditures. Modest expenditures would support intensive monitoring during the highest-risk period that follows psychiatric hospitalization.
OBJECTIVES: Department of Veterans Affairs (VA) patients in depression treatment have high suicide rates after psychiatric hospitalization, antidepressant starts, and dosage changes. Policy makers have recommended closer monitoring during these periods to reduce suicide. This study assessed the frequency of high-risk periods in clinical settings, the levels of monitoring provided during these periods, and the estimated costs of providing monitoring consistent with the most stringent Food and Drug Administration recommendation for treatment periods after antidepressant change (seven visits in the first 12 weeks). METHODS: Monitoring visits were identified in the 12-week period after antidepressant starts and dosage changes and after discharge from psychiatric hospitalization for 100,000 randomly selected VA patients in depression treatment between April 1, 1999, and September 30, 2004. Incremental costs of providing intensive monitoring were estimated by using VA Health Economics Resource Center average cost data. RESULTS: Patients averaged less than one high-risk period each year. They completed an average of 2.4 monitoring visits during the 12-week period after antidepressant treatment events and 4.9 visits after psychiatric hospitalization. Providing intensive monitoring would cost an additional $408-$537 for each high-risk period after antidepressant treatment events and $313-$341 for each high-risk period after psychiatric hospitalization. During fiscal year 2004 providing intensive monitoring during all high-risk periods would have cost an additional $183-$270 million. Providing intensive monitoring only after psychiatric hospitalizations would have cost an additional $15-$17 million. CONCLUSIONS: Providing intensive monitoring for VA patients in depression treatment during all high-risk periods for suicide would require substantial services reorganization and incremental expenditures. Modest expenditures would support intensive monitoring during the highest-risk period that follows psychiatric hospitalization.
Authors: Robert J Valuck; Anne M Libby; Heather D Orton; Elaine H Morrato; Richard Allen; Ross J Baldessarini Journal: Am J Psychiatry Date: 2007-08 Impact factor: 18.112
Authors: J John Mann; Alan Apter; Jose Bertolote; Annette Beautrais; Dianne Currier; Ann Haas; Ulrich Hegerl; Jouko Lonnqvist; Kevin Malone; Andrej Marusic; Lars Mehlum; George Patton; Michael Phillips; Wolfgang Rutz; Zoltan Rihmer; Armin Schmidtke; David Shaffer; Morton Silverman; Yoshitomo Takahashi; Airi Varnik; Danuta Wasserman; Paul Yip; Herbert Hendin Journal: JAMA Date: 2005-10-26 Impact factor: 56.272
Authors: Mark Olfson; Steven C Marcus; Benjamin Druss; Lynn Elinson; Terri Tanielian; Harold Alan Pincus Journal: JAMA Date: 2002-01-09 Impact factor: 56.272
Authors: Chuan-Fen Liu; Susan C Hedrick; Edmund F Chaney; Patrick Heagerty; Bradford Felker; Nicole Hasenberg; Stephan Fihn; Wayne Katon Journal: Psychiatr Serv Date: 2003-05 Impact factor: 3.084
Authors: Chuan-Fen Liu; John Fortney; Susan Vivell; Karen Vollen; William N Raney; Barbara Revay; Maurilio Garcia-Maldonado; Jeffrey Pyne; Lisa V Rubenstein; Edmund Chaney Journal: Am J Manag Care Date: 2007-12 Impact factor: 2.229
Authors: Kara Zivin; H Myra Kim; John F McCarthy; Karen L Austin; Katherine J Hoggatt; Heather Walters; Marcia Valenstein Journal: Am J Public Health Date: 2007-10-30 Impact factor: 9.308
Authors: Bret R Rutherford; Jane Tandler; Patrick J Brown; Joel R Sneed; Steven P Roose Journal: Am J Geriatr Psychiatry Date: 2013-11-05 Impact factor: 4.105
Authors: Hyungjin Myra Kim; Daniel Eisenberg; Dara Ganoczy; Katherine Hoggatt; Karen L Austin; Karen Downing; John F McCarthy; Mark Ilgen; Marcia Valenstein Journal: Health Serv Res Date: 2010-10 Impact factor: 3.402
Authors: John Kasckow; Susan Zickmund; John Gurklis; James Luther; Lauren Fox; Melissa Taylor; Ira Richmond; Gretchen L Haas Journal: Psychiatry Res Date: 2016-02-24 Impact factor: 3.222
Authors: Chris Poulin; Brian Shiner; Paul Thompson; Linas Vepstas; Yinong Young-Xu; Benjamin Goertzel; Bradley Watts; Laura Flashman; Thomas McAllister Journal: PLoS One Date: 2014-01-28 Impact factor: 3.240
Authors: C Hyung Keun Park; Jae Won Lee; Sang Yeol Lee; Jungjoon Moon; Se Hoon Shim; Jong Woo Paik; Shin Gyeom Kim; Seong Jin Cho; Min Hyuk Kim; Seokho Kim; Jae Hyun Park; Sungeun You; Hong Jin Jeon; Yong Min Ahn Journal: J Korean Med Sci Date: 2017-09 Impact factor: 2.153